TSC Ltd.

Wolverton Mill, United Kingdom
Wolverton Mill, United Kingdom
SEARCH FILTERS
Time filter
Source Type

— Orbis Research delivers key insights on the global Telecom Service Assurance market in a new report titled “Global Telecom Service Assurance Market by Deployment Type (On Premise, Hosted), Service (System Integration, Operations Management, Engineering and Maintenance, Consulting and Planning), Systems (Probe Systems, Network Management, Workforce Management, Fault Management, Quality Monitoring), Geography, Trends, Forecast (2017-2022)” In this report, Orbis Research sheds light on the various factors and trends impacting market growth over the forecast period. The Global Telecom Service Assurance Market is valued at USD 3.68 billion in 2016 and is expected to reach a value of USD 5.71 billion by the end of 2022, growing at a projected CAGR of 7.6% during the forecast period of 2017 - 2022. Telecom Service Assurance (TSA) are a set of tools and technologies used to optimize the network operations for a service provider. Telecom services are shifting the paradigm by focusing on consumer specific approach, rather than the traditional network centric approach. TSA solutions enable service providers to use the available infrastructure efficiently and also offer reliable service operations. Using TSA Issues can be addressed faster in real-time, and also easy automation and reliable services can be realized. All these factors along with increased demand for connectivity are increased the demand for telecom Service Assurance Solutions. High optimization and increased cost saving are driving the growth of this market. Service providers are now looking for advanced solutions so as to better optimize the network and provide value added services on the available infrastructure which is helping the growth of TSA solutions. However high initial cost and slow adoption rate in developing countries is hindering the growth of this technology. Telecom Service Assurance market can segmented based on many parameters by deployment type (On-Premise and Hosted), by Service (System Integration, Operations Management, Maintenance, Consulting and Planning, and Others) by System (Probe Systems, Network Management, Workforce Management, Fault Management, Quality monitoring, and Others) and by Geography (North America, Asia Pacific, Latin America, Europe, and Middle East and Africa). This report also considers key trends impacting the market and includes key profiles of leading players in TSC market which include Nokia Solutions, CA Technologies, Cisco Systems, Tata Consultancy Services, Accenture, IBM Corporation, JDS Corporation, Hewlett-Packard, Ericsson, NEC Corporation and Others. This report describes a detailed study of the Porter's five forces analysis of the market. All the five major factors in these markets have been quantified using the internal key parameters governing each of them. It also covers the market landscape of top players which includes the key growth strategies, geographical footprint, and competition analysis. What the report offers • Market Definition for Telecom Service Assurance along with identification of key drivers and restraints for the market. • Market analysis for the Global Telecom Service Assurance Market, with region specific assessments and competition analysis on a global and regional scale. • Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale. • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares. • Identification and analysis of the Macro and Micro factors that affect the Telecom Service Assurance market on both global and regional scale. • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information Table of Content: 1. Introduction 1.1 Study Deliverables 1.2 Key Findings of The Study 1.3 Research Methodology 3. Market Overview 3.1 Overview 3.2 Porters Five Force Analysis 3.2.1 Threat of New Entrants 3.2.2 Bargaining Power of Consumers 3.2.3 Bargaining Power of Suppliers 3.2.4 Threat of Substitute Products and Services 3.2.5 Intensity of Competitive Rivalry 5. Global Telecom Service Assurance Market Segmentation 5.1 By Deployment Type 5.1.1 On-Premise 5.1.2 Hosted 5.2 By Service 5.2.1 System Integration 5.2.2 Operations Management 5.2.3 Engineering & Maintenance 5.2.4 Consulting and Planning 5.2.5 Others 5.3 By Systems 5.3.1 Probe Systems 5.3.2 Netwok Management 5.3.3 Workforce Management 5.3.4 Fault Management 5.3.5 Quality Monitoring 5.3.6 Others About Us: Orbis Research is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required Market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/global-telecom-service-assurance-market-by-deployment-type--on-premise-hosted-service-system-integration-operations-management-engineering-and-maintenance-consulting-and-planning-systems-probe-systems-netwok-management-workforce-management-fault-managemen


Trump and DOJ, Under AG Jeff Sessions, Continue Hard Line on Military Contract Fraud and FCA Case Initiated Under Former AG Sally Yates Moss & Gilmore LLP announced today on behalf of their client Kamal Al-Sultan, a Kuwaiti businessman and U.S. military contractor of base camp logistics and support, the settlement of a whistleblower lawsuit initiated by Mr. Al Sultan in 2005. The suit alleged fraud on the part of publically traded Kuwaiti based Agility Public Warehousing Company "("PWC") and its affiliate, The Sultan Center ("TSC"). PWC was the prime vendor to feed U.S. and coalition troops in Iraq, Iran and Jordan from 2003–2010, pursuant to $8.5 billion worth of prime-vendor food contracts. As a result of Mr. Al Sultan's whistleblower suit, beginning in November 2009, the Department of Justice's Office in the Northern District of Georgia, under the leadership of then Acting U.S. Attorney Sally Yates, joined Mr. Al Sultan's whistleblower lawsuit (filed in November 2005 by his attorney Raymond L. Moss of Moss & Gilmore LLP) and criminally indicted PWC and TSC (https://www.justice.gov/opa/pr/us-joins-false-claims-act-lawsuit-against-kuwait-based-companies-supplied-food-us-troops). In 2010, the U.S. government suspended PWC and TSC and nearly 300 of their officers, directors, employees, subsidiaries and affiliates from contracting. Under agreements finalized today, PWC has agreed to pay $95 million and relinquish significant potential claims in pending litigation claims filed by PWC against the Defense Logistics Agency arising under the Contract Disputes Act related to additional payments due under these prime vendor contracts. As part of the settlement, PWC agreed to enter a criminal guilty plea to a misdemeanor count of Theft of Government Property, in violation of Title 18 United States Code, Section 641. Defendants agreed to resolve the civil allegations against them without acknowledging any wrongdoing The settlement and guilty plea are subject to Court approval by Judge Thomas Thrash, the Chief Judge of the Northern District of Georgia. (The civil complaint, selected pleadings, rulings by Judge Thrash, settlement agreement and criminal plea are available at http://www.agilitytscusprimevendorlawsuit.com.) The settlement resolves other allegations as well, including PWC and TSC's deliberate violation of the False Claims Act and other federal laws by: According to whistleblower Mr. Al Sultan, "Raymond Moss and his team at Moss & Gilmore were highly effective, skilled and tenacious advocates over this entire 13-year battle. They never took their foot off the gas and, with DOJ, went toe to toe against six of the largest and most powerful law firms in the country." "This is one of the largest military procurement fraud cases in the history of the False Claims Act, passed by Abraham Lincoln to combat war profiteers and one of the largest whistleblower awards ever in a military-procurement fraud case," said Raymond Moss, Mr. Al Sultan's lawyer. "Mr. Al Sultan's unrelenting perseverance to see justice done for U.S. taxpayers and the troops who bravely fought in the two Iraq Wars to protect Kuwait, is awe inspiring and a classic David vs. Goliath story. This case proves the power and efficacy of the False Claims Act to right wrongs and expose and deter fraud anywhere in the world." The filing of Mr. Al Sultan's lawsuit in 2005—and its resulting DOJ investigation—resulted in sweeping governmental changes in prime food vendor contracts to reflect greater pricing transparency, prohibitions on kickbacks and rebates and prompt payment discounts, saving the U.S. government and taxpayers billions of dollars. Mr. Al Sultan's whistleblower lawsuit also spawned the initiation of other DOJ investigations, whistleblower lawsuits, prosecutions settlements and convictions against other prime vendors and their suppliers for similar conduct. "As the great ancient Roman politician and lawyer Cicero once said, 'Any man can make a mistake, only a fool keeps making the same one,'" said Mr. Al Sultan. The two criminal and civil cases were investigated by a joint team, including the various branches of the Department of Justice, special agents of Defense Criminal Investigative Service, the Federal Bureau of Investigation, Army Criminal Investigative Command, auditors from the Defense Contract Audit Agency and the Department of Defense and the Office of Inspector General. The government civil investigation and settlement of these allegations were jointly handled by the United States Attorney's Office in the Northern District of Georgia through Civil Chief Amy Berne and Assistant Branch Director Michael Tingle, and Assistant United States Attorneys Art Coulter and Patrick Klein of the Commercial Frauds Branch of the Civil Division, all in Washington, D.C. The False Claims Act fosters a private-public partnership to fight fraud against the government. The law encourages whistleblowers to file civil lawsuits against companies that are defrauding the government by offering job protection against retaliation and a reward of 15 to 25 percent of the government's civil recovery if the government joins or intervenes in the case. Under the False Claims Act, the United States may recover three times the amount of losses, plus civil penalties. About Moss & Gilmore LLP: With offices in Atlanta and New York, Moss & Gilmore LLP represents whistleblowers in the U.S. and worldwide in federal and state false claim whistleblower and related retaliation cases, involving healthcare fraud and military procurement fraud.  Moss & Gilmore LLP represents whistleblowers in cases under the False Claims Act and claims under the U.S. Securities and Exchange Commission, Commodity Futures Trading Commission involving securities and commodities fraud and IRS whistleblower reward programs. For more information, visit www.mossgilmorelaw.com.


– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control – – First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments – LONDON, May 24, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. There are currently no treatments approved by the U.S. Food and Drug Administration (FDA) for Dravet syndrome, a rare form of epilepsy associated with a high mortality rate and significant developmental delays. Results from this study represent the only well-controlled clinical evaluation of a cannabinoid medication for this devastating and drug-resistant condition. The New Drug Application for Epidiolex remains on track for submission to the FDA in the middle of 2017. "Dravet syndrome is one of the most difficult types of epilepsy to treat and many of the children in this study were experiencing dozens, even hundreds, of seizures per month despite taking multiple concurrent anti-epileptic medications," said Orrin Devinsky, M.D., of NYU Langone Medical Center's Comprehensive Epilepsy Center and lead author of the study. “These results suggest that Epidiolex can provide clinically meaningful benefits and I look forward to the prospect of an appropriately standardized and tested pharmaceutical formulation of cannabidiol available as a treatment option for these patients.” "The publication of these highly-anticipated positive results represents an important milestone for the Dravet syndrome community in that it provides hope that a new treatment option is within sight for this rare and devastating disease," said Nicole Villas, Scientific Director of the Dravet Syndrome Foundation. "As a foundation dedicated to research and patient assistance, we hope the burden of Dravet syndrome on patients and families is recognized and welcome new, well-researched treatments such as this that might help ease the burden." The study randomized 120 children ages two to 18 years (mean age 9.8), with Dravet syndrome whose seizures were not controlled by their current anti-epileptic regimen, to receive either Epidiolex (20mg/kg/day) or placebo in addition to standard treatment. Conducted in 23 study centers in the United States and Europe, patients in the study had tried a median of four prior anti-epileptic drugs (range 0-26) and were taking a median of three (range 1-5) during the study. At baseline, patients had a median frequency of 13 convulsive seizures per month, with a wide range of 3.7 to 1,717 seizures per month. Over the 14-week treatment period, patients taking Epidiolex had a significantly greater median reduction in convulsive seizures (39 percent) compared to placebo (13 percent). The estimated median treatment difference between groups was 23 percent (p=0.01). The proportion of patients who had a 50 percent or better reduction in convulsive seizure frequency was 43 percent with Epidiolex versus 27 percent with placebo (p=0.08). The study also measured improvement on the Caregiver Global Impression of Change (CGIC) scale. Sixty-two percent of patients treated with Epidiolex were rated as improved in overall condition on the CGIC compared to 34 percent of the placebo group (p=0.02). Additionally, more patients became seizure-free on Epidiolex than placebo (5 percent vs 0 percent: p=0.08) and total monthly seizure count was significantly reduced with Epidiolex (p=0.03). Epidiolex was generally well tolerated in the trial. The most common adverse events (AEs) (>10 percent) were somnolence, diarrhea, decreased appetite, fatigue, vomiting, pyrexia, lethargy, convulsion, upper respiratory tract infection. Of the 93 percent of patients on Epidiolex that experienced an AE, 84 percent reported it to be mild or moderate. Ten patients on Epidiolex experienced a serious adverse event compared with three patients on placebo. Eight patients on Epidiolex discontinued treatment due to adverse events compared with one patient on placebo. Elevations in liver enzymes occurred in 12 patients taking Epidiolex and one patient taking placebo, all of whom were on concomitant valproic acid. Four of these patients withdrew from the trial, three on Epidiolex and one on placebo. In the remaining nine patients taking Epidiolex, elevations returned to normal while on treatment. “The publication of results from this landmark study by The New England Journal of Medicine and the accompanying editorial commentary2 highlight the potential of Epidiolex to address the significant unmet need in Dravet syndrome,” said Justin Gover, GW's Chief Executive Officer. “We remain committed to these patients and their families, and are determined to make this important new medicine available to them as quickly as possible.” Dravet syndrome is a severe infantile-onset and highly treatment-resistant epileptic syndrome frequently associated with a genetic mutation in sodium channels. Onset of Dravet syndrome occurs during the first year of life in previously healthy and developmentally normal infants. Initial seizures are often temperature related, severe, and long-lasting. Over time, people with Dravet syndrome can develop multiple types of seizures, including tonic-clonic, myoclonic, and atypical absences and are prone to bouts of prolonged seizures called status epilepticus, which can be life threatening. Risk of premature death including SUDEP (sudden unexpected death in epilepsy) is elevated in people with Dravet syndrome. Additionally, the majority will develop moderate to severe intellectual and development disabilities and require lifelong supervision and care. There are currently no FDA-approved treatments and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Epidiolex, GW's lead cannabinoid product candidate, is a liquid formulation of plant-derived cannabidiol (CBD), which is in development for the treatment of a number of rare childhood-onset epilepsy disorders. GW has conducted extensive pre-clinical research of CBD in epilepsy since 2007. This research has shown that CBD has significant anti-epileptiform and anticonvulsant activity using a variety of in-vitro and in-vivo models and efficacy in reducing seizures in acute animal models of epilepsy. To date, GW has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Epidiolex for the treatment of Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS), each of which are severe infantile-onset, drug-resistant epilepsy syndromes. Additionally, GW has received Fast Track Designation from the FDA for the treatment of Dravet syndrome and Orphan Designation from the European Medicines Agency, or EMA, for Epidiolex for the treatment of Dravet syndrome and LGS. GW is currently evaluating additional clinical development programs in other orphan seizure disorders. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. In the United States, GW operates through its subsidiary Greenwich Biosciences, Inc. For further information, please visit www.gwpharm.com. This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Epidiolex® and the safety profile and commercial potential of Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission, including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. PDFs accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0e56d80b-2ae0-4b73-aae4-02645d14c8a0 http://www.globenewswire.com/NewsRoom/AttachmentNg/71639bb9-ccd0-468d-920e-7aae9bafcc70 http://www.globenewswire.com/NewsRoom/AttachmentNg/a573f62d-8bc6-488e-8a68-9f22e69034c5 A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3159234c-082c-4923-bb4a-7e9dd0e05f63 These photos are also available via AP PhotoExpress. 1 Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376;2011-20. 2 Berkovic, SF. Editorial: Cannabinoids for epilepsy – real data, at last. N Engl J Med 2017; 376;2075-76.


– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control – – First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments – LONDON, May 24, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. There are currently no treatments approved by the U.S. Food and Drug Administration (FDA) for Dravet syndrome, a rare form of epilepsy associated with a high mortality rate and significant developmental delays. Results from this study represent the only well-controlled clinical evaluation of a cannabinoid medication for this devastating and drug-resistant condition. The New Drug Application for Epidiolex remains on track for submission to the FDA in the middle of 2017. "Dravet syndrome is one of the most difficult types of epilepsy to treat and many of the children in this study were experiencing dozens, even hundreds, of seizures per month despite taking multiple concurrent anti-epileptic medications," said Orrin Devinsky, M.D., of NYU Langone Medical Center's Comprehensive Epilepsy Center and lead author of the study. “These results suggest that Epidiolex can provide clinically meaningful benefits and I look forward to the prospect of an appropriately standardized and tested pharmaceutical formulation of cannabidiol available as a treatment option for these patients.” "The publication of these highly-anticipated positive results represents an important milestone for the Dravet syndrome community in that it provides hope that a new treatment option is within sight for this rare and devastating disease," said Nicole Villas, Scientific Director of the Dravet Syndrome Foundation. "As a foundation dedicated to research and patient assistance, we hope the burden of Dravet syndrome on patients and families is recognized and welcome new, well-researched treatments such as this that might help ease the burden." The study randomized 120 children ages two to 18 years (mean age 9.8), with Dravet syndrome whose seizures were not controlled by their current anti-epileptic regimen, to receive either Epidiolex (20mg/kg/day) or placebo in addition to standard treatment. Conducted in 23 study centers in the United States and Europe, patients in the study had tried a median of four prior anti-epileptic drugs (range 0-26) and were taking a median of three (range 1-5) during the study. At baseline, patients had a median frequency of 13 convulsive seizures per month, with a wide range of 3.7 to 1,717 seizures per month. Over the 14-week treatment period, patients taking Epidiolex had a significantly greater median reduction in convulsive seizures (39 percent) compared to placebo (13 percent). The estimated median treatment difference between groups was 23 percent (p=0.01). The proportion of patients who had a 50 percent or better reduction in convulsive seizure frequency was 43 percent with Epidiolex versus 27 percent with placebo (p=0.08). The study also measured improvement on the Caregiver Global Impression of Change (CGIC) scale. Sixty-two percent of patients treated with Epidiolex were rated as improved in overall condition on the CGIC compared to 34 percent of the placebo group (p=0.02). Additionally, more patients became seizure-free on Epidiolex than placebo (5 percent vs 0 percent: p=0.08) and total monthly seizure count was significantly reduced with Epidiolex (p=0.03). Epidiolex was generally well tolerated in the trial. The most common adverse events (AEs) (>10 percent) were somnolence, diarrhea, decreased appetite, fatigue, vomiting, pyrexia, lethargy, convulsion, upper respiratory tract infection. Of the 93 percent of patients on Epidiolex that experienced an AE, 84 percent reported it to be mild or moderate. Ten patients on Epidiolex experienced a serious adverse event compared with three patients on placebo. Eight patients on Epidiolex discontinued treatment due to adverse events compared with one patient on placebo. Elevations in liver enzymes occurred in 12 patients taking Epidiolex and one patient taking placebo, all of whom were on concomitant valproic acid. Four of these patients withdrew from the trial, three on Epidiolex and one on placebo. In the remaining nine patients taking Epidiolex, elevations returned to normal while on treatment. “The publication of results from this landmark study by The New England Journal of Medicine and the accompanying editorial commentary2 highlight the potential of Epidiolex to address the significant unmet need in Dravet syndrome,” said Justin Gover, GW's Chief Executive Officer. “We remain committed to these patients and their families, and are determined to make this important new medicine available to them as quickly as possible.” Dravet syndrome is a severe infantile-onset and highly treatment-resistant epileptic syndrome frequently associated with a genetic mutation in sodium channels. Onset of Dravet syndrome occurs during the first year of life in previously healthy and developmentally normal infants. Initial seizures are often temperature related, severe, and long-lasting. Over time, people with Dravet syndrome can develop multiple types of seizures, including tonic-clonic, myoclonic, and atypical absences and are prone to bouts of prolonged seizures called status epilepticus, which can be life threatening. Risk of premature death including SUDEP (sudden unexpected death in epilepsy) is elevated in people with Dravet syndrome. Additionally, the majority will develop moderate to severe intellectual and development disabilities and require lifelong supervision and care. There are currently no FDA-approved treatments and nearly all patients continue to have uncontrolled seizures and other medical needs throughout their lifetime. Epidiolex, GW's lead cannabinoid product candidate, is a liquid formulation of plant-derived cannabidiol (CBD), which is in development for the treatment of a number of rare childhood-onset epilepsy disorders. GW has conducted extensive pre-clinical research of CBD in epilepsy since 2007. This research has shown that CBD has significant anti-epileptiform and anticonvulsant activity using a variety of in-vitro and in-vivo models and efficacy in reducing seizures in acute animal models of epilepsy. To date, GW has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for Epidiolex for the treatment of Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS), each of which are severe infantile-onset, drug-resistant epilepsy syndromes. Additionally, GW has received Fast Track Designation from the FDA for the treatment of Dravet syndrome and Orphan Designation from the European Medicines Agency, or EMA, for Epidiolex for the treatment of Dravet syndrome and LGS. GW is currently evaluating additional clinical development programs in other orphan seizure disorders. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood-onset epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. In the United States, GW operates through its subsidiary Greenwich Biosciences, Inc. For further information, please visit www.gwpharm.com. This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Epidiolex® and the safety profile and commercial potential of Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission, including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. PDFs accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0e56d80b-2ae0-4b73-aae4-02645d14c8a0 http://www.globenewswire.com/NewsRoom/AttachmentNg/71639bb9-ccd0-468d-920e-7aae9bafcc70 http://www.globenewswire.com/NewsRoom/AttachmentNg/a573f62d-8bc6-488e-8a68-9f22e69034c5 A video accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3159234c-082c-4923-bb4a-7e9dd0e05f63 These photos are also available via AP PhotoExpress. 1 Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376;2011-20. 2 Berkovic, SF. Editorial: Cannabinoids for epilepsy – real data, at last. N Engl J Med 2017; 376;2075-76.


News Article | May 15, 2017
Site: www.prnewswire.com

Officially launched in 2014 with the TS Alliance of Israel, the TS Alliance's Global Alliance program was created to address unmet needs within the global TSC community at the country level.  This program provides the opportunity for the TS Alliance to share experiences and assist in the start-up or support of TSC-related organizations in other countries. A Global Alliance is a structured group of empowered and caring volunteers who work closely with the TS Alliance to facilitate local connections for individuals and families affected by TSC, raise revenue and increase awareness while supporting the mission of the organization.  The TS Alliance also has a formal partnership with Tuberous Sclerosis Canada Sclérose Tubéreuse. "The TS Alliance is thrilled to partner with this new organization in Mexico," said TS Alliance President & CEO Kari Luther Rosbeck. "We look forward to working with them to advocate for people with TSC, provide educational programs, increase awareness and offer assistance with fundraising. Of course, the ultimate goal is to improve outcomes for everyone with TSC." The TS Alliance is dedicated to finding a cure for tuberous sclerosis complex, while improving the lives of those affected. Founded in 1974, it works to improve quality of life for individuals and families affected by TSC by stimulating and sponsoring research; creating programs, support services and resource information; and developing and implementing public and professional programs designed to heighten awareness of the disease. For more information about the TS Alliance of Mexico, visit www.tsallianceofmexico.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tuberous-sclerosis-alliance-announces-new-global-partnership-in-mexico-300457208.html


News Article | May 8, 2017
Site: www.eurekalert.org

HOUSTON - (May 8, 2017) - A clinical trial of a drug that researchers hope can prevent or delay the onset of epilepsy in children with tuberous sclerosis has begun at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). The Houston site, one of just seven in the country, is led by Mary K. Koenig, M.D., associate professor and Endowed Chair of Mitochondrial Medicine in the Division of Neurology of the Department of Pediatrics at McGovern Medical School at UTHealth. "It could potentially be a game-changer for epilepsy in general as it is the first trial ever aimed at preventing seizures from developing in a vulnerable population," Koenig said. Tuberous sclerosis complex (TSC) is a genetic disorder that causes tumors to form in many different organs, including the brain. It can affect neurologic functions, leading to seizures, developmental delay, intellectual disability and autism. According to published research by Harvard, about 80 percent of children with TSC develop epilepsy within the first three years of life. Funded by the National Institutes of Health, the clinical trial will recruit a total of 80 infants with TSC. At the first sign of abnormal brain activity revealed by electroencephalogram, half the infants will receive vigabatrin, a medication used to control infantile spasms, while the other half receive placebo. At the onset of clinical seizures, all of the children will transition to the standard of care for infants with TSC and seizures. The investigators will follow the children for three years to monitor developmental progress and the onset and severity of seizures. The study, called Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex, will target the window of time between abnormal brain activity and the onset of seizures, which is usually two to three months. The researchers are hoping to determine whether early intervention will have a positive effect on developmental outcomes and delay or prevent the onset of seizures. For more information about the clinical trial, please call 713-500-5766. Patients in the study will be seen at UT Physicians Pediatric Neurology at Texas Medical Center. UT Physicians is the clinical practice of McGovern Medical School.


- Epidiolex® NDA submission expected mid-year - - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology - - Conference call today at 4:30 p.m. EDT- LONDON, May 09, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter ended 31 March 2017.                                        “Our primary focus is on the submission of the Epidiolex NDA, which is expected in the middle of this year. Based on the efficacy and safety profile, we are confident in the prospects for an Epidiolex approval and continue to expand the commercial organization in preparation for a highly successful launch,” stated Justin Gover, GW’s Chief Executive Officer. “Beyond Epidiolex, we continue to advance a number of additional exciting clinical programs.” • Epidiolex (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS) Solely for the convenience of the reader, the above balances have been translated into U.S. dollars at the rate on 31 March 2017 of $1.25331 to £1. These translations should not be considered representations that any such amounts have been, could have been or could be converted into U.S. dollars at that or any other exchange rate as at that or any other date. Conference Call and Webcast Information GW Pharmaceuticals will host a conference call and webcast to discuss the second quarter 2017 financial results today at 4:30 pm EDT. To participate in the conference call, please dial 800-860-2442 (toll free from the U.S. and Canada) or 412-858-4600 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at http://www.gwpharm.com. A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010, (international):1-919-882-2331. For both dial-in numbers please use conference ID # 13661781. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 31 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com. This news release contains forward-looking statements that reflect GW's current expectations regarding future events, including statements regarding financial performance, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions, the relevance of GW products commercially available and in development, the clinical benefits of Sativex and Epidiolex and the safety profile and commercial potential of Sativex and Epidiolex. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including (inter alia), the success of GW’s research strategies, the applicability of the discoveries made therein, the successful and timely completion of uncertainties related to the regulatory process, and the acceptance of Sativex, Epidiolex and other products by consumer and medical professionals. A further list and description of risks and uncertainties associated with an investment in GW can be found in GW’s filings with the U.S. Securities and Exchange Commission including the most recent Form 20-F filed on 5 December 2016. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. GW undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Condensed consolidated statement of comprehensive loss For the three months ended 31 March 2017 Condensed consolidated statement of comprehensive loss For the six months ended 31 March 2017 GW Pharmaceuticals plc Condensed consolidated statement of changes in equity Six months ended 31 March 2017


— “Global RFID and barcode printer market to exhibit significant growth between 2017 and 2022” The RFID and barcode printer market is expected to grow at a CAGR of 5.7% between 2017 and 2022 to reach USD 4.81 billion by 2022. The key driving factors for the growth of this market include the growth of the e-commerce industry; rising demand for extracting data in various manufacturing, retail, transportation and logistics industries; and elimination of human errors. However, poor quality of print in barcode and RFID labels and tags are restraining the growth of the RFID and barcode printer market. Browse 62 market data tables and 80 figures spread through 181 pages and in-depth TOC on "RFID and Barcode Printer Market - Global Forecast to 2022" “Industrial printers to dominate the RFID and barcode printer market during the forecast period” Industrial printers held the largest size of the RFID and barcode printer market in 2016.Industrial printers in manufacturing industry are used for applications such as address labels, apparel tagging, apparel tags, asset tracking, automotive labeling, incoming goods labeling, item identification. Logistic tracking, pallet labeling, paper/pulp labeling, price labeling, price ticketing, product and service information, and product fact tags are the applications in which these printers are used to print the labels and tags in the manufacturing industry. Industrial printers are expected to hold the largest size of this market during the forecast period due to the increasing demand in developing countries and the need for real-time information pertaining to the exact location of other assets. “Manufacturing industry to hold a major share of the RFID and barcode printer market during the forecast period” The market for the manufacturing industry is expected to grow at a high rate between 2017 and 2022.RFID and barcode printers are being used in the manufacturing industry in applications such as automated inspection and identification in production process using barcode labels and tags. Labels and tags used in the manufacturing industry to manage the asset lifecycle cost and increase the lifecycle of an equipment as well as reliability. Industrial barcode printers in the manufacturing industry are commonly used to print labels and tags used for track and trace applications and workflow optimization. Order a copy of RFID and Barcode Printer Market by Type (Industrial, Desktop, Mobile), Technology (Thermal Transfer, Direct Thermal, Inkjet), Resolution (Below 300 dpi, 301-600), Connectivity, Industry (Manufacturing, Retail, Healthcare) - Global Forecast to 2022 Research Report at: http://www.rnrmarketresearch.com/contacts/purchase?rname=988518 “APAC to be the fastest-growing market for GNSS chips during the forecast period” APAC is expected to be the fastest-growing market for RFID and barcode printers during the forecast period. The leading companies providing barcode and RFID printers are based in APAC. The Asian markets, especially in Japan and China, are more likely to govern this market in the years to come in terms of adaptability and market size. China currently holds the largest share of the market owing to the higher adoption of barcode and RFID printers in various industries in APAC are fueling the growth of this market in this region. The break-up of the profiles of primary participants for the report has been given below: • By Company Type: Tier 1 – 40%, Tier 2 – 35%, and Tier 3 – 25% • By Designation: C–Level Executives – 62% and Directors– 38% • By Region: North America - 32%, Europe – 28%, APAC – 25%, and RoW – 15% The key players operating in this market include Zebra Technologies Corporation (US), Honeywell International Inc. (US) , Toshiba TEC Corporation (Japan), Sato Holdings Corporation (Japan), TSC Auto ID Technology Co., Ltd. (Taiwan), Avery Dennison Corporation (US) , Wasp Barcode Technologies (US) , Postek Electronics Co., Ltd. (China), Dascom Printer (Jiangmen) Co., Ltd. (China). The research report on the global RFID and barcode printer market covers the market on the basis of type, technology, printing resolution, industry, and geography. The market, on the basis of type, has been segmented into industrial, desktop, and mobile printer. On the basis of technology, the RFID and barcode printer market has been classified into thermal transfer, direct thermal, and inkjet. The market on the basis of printing resolution has been segmented into below 300 dpi, between 301 and 600 dpi, and above 600 dpi. Further, the RFID and barcode printer market on the basis of industry has been segmented into manufacturing, retail, healthcare, government, entertainment, and others. The report covers 4 major geographical regions, namely, North America, Europe, APAC, and RoW. • Illustrative segmentation, analysis, and forecast for the market based on type, technology, printing resolution, industry, and geography have been conducted to give an overall view of the RFID and barcode printer market. • The value chain analysis has been provided for in-depth insight into the RFID and barcode printer market. • The major drivers, restraints, opportunities, and challenges for the RFID and barcode printer market have been detailed in this report. • The report includes a detailed competitive landscape, along with key players, in-depth analysis, and revenue of the key players. Inquire for more Info about RFID and Barcode Printer Market Research Report: https://goo.gl/Tmt7KP ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. For more information, please visit http://www.rnrmarketresearch.com/rfid-and-barcode-printer-market-by-type-industrial-%20desktop-mobile-technology-thermal-transfer-direct-thermal-inkjet-resolution-below-300-dpi-301-600-connectivity-industry-manufacturing-retail-healt-st-to-2022-market-report.html%20


Disclosed is a halogen-free fire-retardant polyolefin resin composition for a telecommunication cable covering, which includes 5074 wt % of thermoplastic polyurethane, 110 wt % of maleic anhydride grafted styrene-ethylene/butylene-styrene, 538 wt % of melamine cyanurate and 220 wt % of an organic phosphinate salt, and in which fire retardancy is maintained, whitening or bleeding is prevented and scratch hardness is high, despite the use of a small amount of fire retardant.

Loading TSC Ltd. collaborators
Loading TSC Ltd. collaborators